Cyclosporine is a drug used to help reduce the risk of rejection of organ and bone marrow transplants by the body. It is also used in clinical trials to make cancer cells more sensitive to anticancer drugs.
With the rapid spread of the virus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) throughout the world, causing the current COVID-19 pandemic, there is an urgent need for new antivirals and vaccines to combat its spread. The current study published on the preprint server bioRxiv in June 2020 shows some of the results of the extensive repurposing of already FDA-approved drugs.
Experience throughout the world, including in Europe, shows that advanced age is the most important risk factor for death in COVID-19: people aged over 70 years are over 10 times more likely to die compared to those aged below 50.
Santen EMEA is delighted to announce that the results of VEKTIS, a twelve month study in pediatric vernal keratoconjunctivitis have been published in the American Journal of Ophthalmology.
Peptides are short chains of amino acids that occur in our body, in plants or bacteria to control diverse functions.
University of Maryland School of Medicine researchers found that lung transplant recipients who had early signs of organ rejection could increase their chances of survival by using an inhaled form of the immunosuppression drug cyclosporine.
As many as 16.5 million adults in America suffer from a skin disease known as atopic dermatitis, an inflammatory disease that results in red, itchy skin.
Sun Pharmaceutical Industries Ltd. today announced that Sun Pharma has received approval for CEQUA (cyclosporine ophthalmic solution) 0.09%, from the U.S. Food and Drug Administration. CEQUA is indicated to increase tear production in patients with keratoconjunctivitis sicca (dry eye).
Elijah Patino is a happy, healthy seven-year-old now, but it took a while to get there. For much of his life, he had a mysterious disease that made it painful to eat and painful to play.
Aurinia Pharmaceuticals Inc., a clinical stage biopharmaceutical company focused on the global immunology market, today announced the initiation of its Phase 2 trial evaluating voclosporin ophthalmic solution (VOS) for the treatment of dry eye syndrome (DES).
An international team led by Johns Hopkins Medicine researchers has conducted what is believed to be the largest detailed published study of people with a poorly understood skin condition known as prurigo nodularis.
The U.S. Food and Drug Administration today expanded the approval of Xeljanz (tofacitinib) to include adults with moderately to severely active ulcerative colitis. Xeljanz is the first oral medication approved for chronic use in this indication.
An analysis of published studies and reports indicates that a number of herbal products may affect the properties of prescription drugs, leading to alterations in the drugs' effectiveness as well as potentially dangerous side effects.
In a new study involving laboratory mice, researchers have found that solenopsin and similar compounds could be beneficial for psoriasis.
Vaccines and cancer immunotherapies do essentially the same thing: They boost a person's immune system, better enabling it to fight an offender, be it microbe or malignancy.
Psoriasis is a much-misunderstood disease, often kept under wraps by sufferers who want to hide their skin lesions.
Approximately 7.5 million people in the United States have psoriasis, and the impact of this disease goes far beyond its visible effects on the skin.
Bring the drugs, hold the suds. That summarizes a promising new drug-making technique designed to reduce serious allergic reactions and other side effects from anti-cancer medicine, testosterone and other drugs that are administered with a needle.
The kidney is the most commonly transplanted organ in the United States, with more than 17,000 transplants performed each year. Following kidney transplant, patients are routinely placed on a regimen of immunosuppressant medications to prevent organ rejection, which often includes calcineurin inhibitors (CNIs) as the backbone medication of this regimen.
A reduction in the risks of infection- and organ failure-related death has driven an improvement in non-relapse mortality among recipients of allogeneic haematopoietic stem cell transplantation, Japanese research suggests.
Immune Pharmaceuticals Inc. announced today that the first patient has been enrolled into the Phase 2 clinical trial evaluating the safety and efficacy of its first in class fully human monoclonal antibody, bertilimumab in Ulcerative Colitis (UC).